Final overall study analysis continues to show benefit of sacituzumab govitecan in advanced HR+ breast cancer
byDana-Farber Cancer InstituteOverall survival in the intention-to-treat population. This is the planned final analysis of overall survival in the intent-to-treat population of all randomly assi
Updated on: January 22,2024
Final overall study analysis continues to show benefit of sacituzumab govitecan in advanced HR+ breast cancer
byDana-Farber Cancer InstituteOverall survival in the intention-to-treat population. This is the planned final analysis of overall survival in the intent-to-treat population of all randomly assi
Updated on:January 22,2024
